Drug profile

The FDA adverse-event record for Feline Leukemia Virus, Kawakami-Theilen

109 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Feline Leukemia Virus, Kawakami-Theilen. See the species affected, top reactions, and outcomes below.

109
adverse-event reports
13.8%
death-coded share
Cat
most-reported species
33
Fever - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
109
Total Reports
15
Deaths Reported
13.8%
Death Rate

Active Ingredients

Feline Leukemia Virus, Kawakami-Theilen

Administration Routes

Subcutaneous

Species Affected

Cat 109

Most Affected Breeds

Domestic Shorthair 71
Domestic Longhair 15
Domestic Mediumhair 7
Cat (other) 5
Siamese 3
Norwegian Forest 2
Selkirk Rex 1
Ragdoll 1
Snowshoe 1
Balinese 1

Most Reported Reactions

Fever 33
Lethargy (see also Central nervous system depression in 'Neurological') 31
Lethargy (see also Central nervous system depression in Neurological) 22
Vomiting 20
Anorexia 20
Not eating 18
Decreased appetite 13
Weight loss 13
Pain NOS 11
Lack of efficacy - NOS 11
Death by euthanasia 10
Hiding 9

Outcome Breakdown

Ongoing
60 (54.5%)
Recovered/Normal
27 (24.5%)
Euthanized
10 (9.1%)
Outcome Unknown
7 (6.4%)
Died
5 (4.5%)
Recovered with Sequela
1 (0.9%)

Feline Leukemia Virus, Kawakami-Theilen Adverse Event Insights

109 reports name Feline Leukemia Virus, Kawakami-Theilen; 15 recorded a death outcome (13.8% of reported events, not a population-level mortality rate). Active ingredient: Feline Leukemia Virus, Kawakami-Theilen. Administration route: Subcutaneous.

By species: Cat (109 reports). By breed: Domestic Shorthair (71), Domestic Longhair (15), Domestic Mediumhair (7).

Leading clinical signs: Fever (33), Lethargy (see also Central nervous system depression in 'Neurological') (31), Lethargy (see also Central nervous system depression in Neurological) (22), Vomiting (20). Outcome, 110 coded reports: Ongoing leads at 54.5%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.